New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)

New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)

Inclusion Criteria:

≥ 50 years of age or older at the time of enrollment

Willing to sign the informed consent form

Must have 2 occurrences from among the below parameters of diabetes mellitus (PDMs) in past 90 days measured in outpatient setting (not in urgent care, emergency room or while inpatient):

FBG ≥126mg/dl HbA1c ≥6.5% RBG ≥ 200mg/dl 2-hour post-glucose ≥200mg/dl (OGTT)

Must have had glycemic parameter measured in 3-18 months prior to screening that did NOT meet DM criteria

Must be willing to provide several tubes of blood without endangering health

No history of pancreatic cancer or other known pancreatic neoplasia

No active cancers within the past 5 years (with the exception of non-melanoma skin cancers resolved/treated > 1 year prior to enrollment and in situ cancers)

Exclusion Criteria:

Prior DM diagnosis

Met criteria for DM ≥91 days prior to enrollment (patients with prior gestational diabetes that has resolved are NOT acceptable to enroll)

Carried a DM diagnosis or used anti-DM medications at a time greater than or equal to 91 days prior to enrollment

Any known pancreatic lesions (aside from diabetes)

Received cancer treatment within the past 5 years (with the exception of treatment of non-melanoma skin cancer), carrying a current cancer diagnosis, and/or being investigated for suspicion of past cancer recurrence.

Current chronic or acute oral steroid use

History of intra-articular steroid injections (<1 week) of the qualifying DM blood test (allowed exception: nasal, topical, oral budesonide)

Any surgery requiring general anesthesia within 2 months of collection

Local anesthetic (including dental novocaine) within 1 week of collection

History or presence of HIV/AIDs, Hepatitis A or E within the past five years, TB, any kind of prion disorder (e.g., CJD)

Blood transfusion within 1 month

Organ transplant recipient

Currently pregnant, or pregnancy within last 12 months

Receipt of systemic immunomodulation therapy within past 12 months

Significant medical condition that in the site investigator’s opinion would compromise the subject’s ability to tolerate study interventions

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 4, 2022Comments | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine